secwatch.observer — SEC 8-K summary
======================================

Issuer:     NORTHWEST BIOTHERAPEUTICS INC (NWBO)
CIK:        0001072379
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001104659-23-001886
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Northwest Biotherapeutics shareholders approve all six proposals at 2022 annual meeting
--------------------------------------------------------------------------------

- Re-elected directors Linda F. Powers and Navid Malik with 97.2% and 97.5% of votes cast respectively.
- Ratified Cherry Bekaert LLP as auditor for FY2022 with 98.8% of votes cast.
- Approved increase of authorized common shares from 1.2B to 1.7B with 95% of votes cast (73.8% of outstanding common).
- Approved advisory say-on-pay for 2021 executive compensation with 91.9% support.
- Ratified 2020 option awards to executives and independent directors with over 90% approval each.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1072379/000110465923001886/0001104659-23-001886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1072379/000110465923001886/tm231540d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-001886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer